| Literature DB >> 27093081 |
Abstract
Formation of new blood vessels in tumors, a process termed tumor angiogenesis, is a crucial step during oncogenic progression. Blocking tumor angiogenesis is therefore expected to have a profound impact on tumor growth. It took several decades of collective efforts to translate this intriguing idea into tangible clinical benefit. Today, anti-angiogenesis agents represent standard-of-care therapies for multiple types of cancers, and the clinical experience has taught us many lessons about the concept and application of anti-angiogenesis. This Perspective is an attempt to summarize these lessons and how they can be leveraged to improve anti-angiogenesis therapy.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27093081 DOI: 10.1016/j.devcel.2016.03.015
Source DB: PubMed Journal: Dev Cell ISSN: 1534-5807 Impact factor: 12.270